Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease
Benzinga,
Idorsia Pharmaceuticals Ltd. / Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new…